Re: Laboratory Services Agreement - Study Number: [ * ] – Amendment No. 1 GlaxoSmithKline LLC (“GSK”) authorised a contract (the “Services Agreement”) with an effective date of 24th April 2014 with diaDexus, Inc (“Contractor”) for the above referenced...Laboratory Services Agreement • August 5th, 2014 • diaDexus, Inc. • Pharmaceutical preparations • Delaware
This change necessitates revision to Schedule B of the Laboratory Services Agreement. Schedule B of the Agreement shall be deleted in its entirety and replaced with the attached Schedule Ba.
LABORATORY SERVICE AGREEMENTLaboratory Service Agreement • August 5th, 2014 • diaDexus, Inc. • Pharmaceutical preparations • Delaware
This Laboratory Service Agreement (this “Agreement”) is made and entered into, effective as of April 24th, 2014 (the “Effective Date’’), by and between diaDexus, Inc., a Delaware corporation with an office at 349 Oyster Point Boulevard, South San Francisco, CA 94080-1913 (“Contractor”), and GlaxoSmithKline LLC, a Delaware limited liability company with an office located at Five Moore Drive, Research Triangle Park, North Carolina 27709 (“GSK”). Contractor and GSK may be referred to herein individually as a “Party”, and collectively as the “Parties”.
TRANSITION AGREEMENTTransition Agreement • August 5th, 2014 • diaDexus, Inc. • Pharmaceutical preparations • California
This Transition Agreement (the “Agreement”) is entered into by and between diaDexus, Inc., a Delaware corporation (the “Company”), and Brian E. Ward (the “Executive”). The Company and the Executive have determined that it is in the best interests of the Company and its stockholders to enter into this Agreement to ensure a smooth transition of the Executive’s duties and on-going projects.
